PEPG250117P3000
- 0.00
- 0.000.00%
PepGen Newsroom
Wedbush Cuts Price Target on PepGen to $8 From $12, Maintains Outperform Rating
Leerink Partners Maintains PepGen(PEPG.US) With Buy Rating
BofA Securities Downgrades PepGen(PEPG.US) to Sell Rating, Cuts Target Price to $3
B of A Securities Maintains Neutral on PepGen, Lowers Price Target to $6
PepGen Inc. (PEPG) Receives a Buy From Stifel Nicolaus
PepGen Is Maintained at Outperform by Wedbush
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $26
Analysts Are Bullish on Top Healthcare Stocks: PepGen Inc. (PEPG), Ligand Pharma (LGND)
PepGen Analyst Ratings
HC Wainwright & Co. Reiterates Buy on PepGen, Maintains $26 Price Target
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Tenaya Therapeutics (TNYA) and PepGen Inc. (PEPG)
Analysts Conflicted on These Healthcare Names: Senseonics Holdings (SENS), PepGen Inc. (PEPG) and 4D Molecular Therapeutics (FDMT)
PepGen Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on PepGen, Maintains $26 Price Target
Optimistic Outlook on PepGen's DMD Therapy Despite Initial Data: Analyst Reiterates Buy Rating
Wedbush Reiterates Outperform on PepGen, Maintains $20 Price Target
PepGen Analyst Ratings
Stifel Nicolaus Keeps Their Buy Rating on PepGen Inc. (PEPG)
Stifel Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $21
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $26